EUVIMEDEUVIMED entdecken
Open Access

Discovery of a 4′‐Azido Fleximer Nucleoside Analog With Broad‐Spectrum Antiviral Activity Against DENV, EBOV, and Other RNA Viruses

Kyle A Davis iD, Ryan L Slack iD, Thomas R Foulkes, Tereza Frčková, Lenka Tomková, Jessica L Smith, Meareg Amare, Grayson D Pipher iD, Peter Halfmann iD, Alec J Hirsch, Luděk Eyer iD, Stefan G Sarafianos iD und 1 weitere

ChemMedChem · 2026

DOI: 10.1002/cmdc.70435 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Kyle A Davis und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, University of Maryland Baltimore County, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Nucleosides, RNA Viruses, Drug Discovery. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, Ministry of Education, Youth and Sports of the Czech Republic within the INTER-EXCELLENCE II program and the INTER-ACTION subprogram, UMBC Technology Catalyst Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ongoing emergence and reemergence of RNA viruses from multiple viral families highlights the urgent need for broad‐spectrum antiviral therapeutics. To address this issue, a series of 4′‐azido fleximer nucleoside analogs were synthesized and evaluated for broad‐spectrum antiviral activity against pathogens of epidemic/pandemic concern. One compound, KAD‐039, featuring a 2′, 3′‐diisobutyrate‐5′‐ProTide prodrug, exhibited potent antiviral activity across flaviviruses, filoviruses, and coronaviruses, with EC 50 values ranging from 1 to 10 µM and minimal cytotoxicity (CC 50 > 50 µM). Pharmacokinetic evaluation of KAD‐039 demonstrated high plasma stability in dog, monkey, and human plasma, with half‐lives ranging from 19.9 to 28 h but exhibited poor stability in human liver microsomes ( t 1/2 = 6.1 min). To help elucidate the mechanism of action of KAD‐039 against these viral families, computational molecular docking studies were performed using the expected triphosphate active form within the cap/GTP‐binding pockets of several viral methyltransferases and showed that KAD‐039TP docked into all of the viral MTases with similar or higher predicted affinity compared to the natural substrate. In addition, KAD‐039TP displayed reduced predicted affinity for the human N7 methyltransferase, suggesting low host toxicity. These results highlight 4′‐azido fleximer analogs as promising broad‐spectrum antivirals, potentially functioning through viral methyltransferase inhibition, and support further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsNucleosidesRNA VirusesDrug DiscoveryDengue VirusHumansAnimalsStructure-Activity RelationshipDogsMicrobial Sensitivity TestsMolecular Docking SimulationMolecular StructureDose-Response Relationship, Drug

Stichwörter der Autor:innen

antiviralbroad‐spectrumfleximernucleosideproTide

Substanzen

Antiviral AgentsNucleosides

Autor:innen und Institutionen

  • Department of Chemistry and Biochemistry, University of Maryland Baltimore County, Baltimore, Maryland, USA.
  • Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Laboratory of Emerging Viral Diseases, Veterinary Research Institute, Brno, Czech Republic.
  • Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
  • Vaccine and Gene Therapy Institute, Oregon Health and Sciences University, Beaverton, Oregon, USA.
  • Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.

ORCID-Profile: Kyle A Davis, Ryan L Slack, Grayson D Pipher, Peter Halfmann, Luděk Eyer, Stefan G Sarafianos, Katherine L Seley-Radtke

Förderung

  • NIGMS NIH HHS
  • Ministry of Education, Youth and Sports of the Czech Republic within the INTER-EXCELLENCE II program and the INTER-ACTION subprogram
  • UMBC Technology Catalyst Fund
  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Davis, K. A., Slack, R. L., Foulkes, T. R., Frčková, T., Tomková, L., Smith, J. L., Amare, M., Pipher, G. D., Halfmann, P., Hirsch, A. J., Eyer, L., Sarafianos, S. G., & Seley-Radtke, K. L. (2026). Discovery of a 4′‐Azido Fleximer Nucleoside Analog With Broad‐Spectrum Antiviral Activity Against DENV, EBOV, and Other RNA Viruses. ChemMedChem. https://doi.org/10.1002/cmdc.70435

Vancouver

Davis KA, Slack RL, Foulkes TR, Frčková T, Tomková L, Smith JL, et al. Discovery of a 4′‐Azido Fleximer Nucleoside Analog With Broad‐Spectrum Antiviral Activity Against DENV, EBOV, and Other RNA Viruses. ChemMedChem. 2026. doi:10.1002/cmdc.70435

BibTeX
@article{Davis2026,
  author = {Davis, Kyle A and Slack, Ryan L and Foulkes, Thomas R and Frčková, Tereza and Tomková, Lenka and Smith, Jessica L and Amare, Meareg and Pipher, Grayson D and Halfmann, Peter and Hirsch, Alec J and Eyer, Luděk and Sarafianos, Stefan G and Seley-Radtke, Katherine L},
  title = {Discovery of a 4′‐Azido Fleximer Nucleoside Analog With Broad‐Spectrum Antiviral Activity Against DENV, EBOV, and Other RNA Viruses},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.70435}
}
Kostenlos starten →